Vaccinex

VCNXPhase 2

Vaccinex is dedicated to discovering and developing innovative biologics to treat serious diseases, with a core focus on its proprietary SEMA4D (Semaphorin 4D) platform. The company's lead asset, pepinemab, is a first-in-class monoclonal antibody designed to block SEMA4D, a key regulator of inflammatory and immune responses implicated in neurodegeneration and tumor progression. While facing significant clinical and financial challenges, Vaccinex continues to advance its pipeline through strategic collaborations and clinical trials aimed at validating its novel therapeutic approach.

Market Cap

$2.4M

Employees

11-50

Focus

Biotech

AI Company Overview

Technology Platform

Proprietary ACTIVMAb® platform for discovering fully human monoclonal antibodies, with a therapeutic focus on modulating the SEMA4D (Semaphorin 4D) pathway to treat neuroinflammation and cancer.

Pipeline Snapshot

8 drugs in pipeline

Drug	Indication	Stage
VX15/2503 + Placebo	Huntington's Disease	Phase 2
Pepinemab + Placebo	Alzheimer Disease	Phase 1/2
Avelumab and Pepinemab	Metastatic Pancreatic Adenocarcinoma	Phase 1/2
Anti-SEMA4D Monoclonal Antibody VX15/2503 + Ipilimumab + Nivolumab	Colon Carcinoma Metastatic in the Liver	Phase 1
VX15/2503 + Placebo	Multiple Sclerosis	Phase 1

Opportunities

Positive clinical data in Alzheimer's or Huntington's disease could validate the SEMA4D platform and attract a major pharmaceutical partner for further development and commercialization.

The novel mechanism in neuroinflammation addresses a high-unmet need in large neurodegenerative markets.

Out-licensing the oncology antibody portfolio could provide non-dilutive funding.

Risk Factors

Severe financial constraints with a high risk of insolvency if additional capital is not secured.

Clinical efficacy of lead candidate pepinemab remains unproven in pivotal settings.

Heavy reliance on positive data from a single, small trial (SIGNAL-AD) for near-term valuation support.

Intense competition in both neurology and oncology therapeutic areas.

Competitive Landscape

In neurology, competes with huntingtin-lowering therapies (Wave, uniQure) in Huntington's and anti-amyloid antibodies (Eisai/Biogen, Lilly) in Alzheimer's, but offers a differentiated neuroinflammation mechanism. In oncology, the SEMA4D space includes Kadmon/Sanofi, but Vaccinex's clinical focus has shifted away from competitive immuno-oncology combinations.